<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614741</url>
  </required_header>
  <id_info>
    <org_study_id>R18098M</org_study_id>
    <nct_id>NCT03614741</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Pharmacokinetics of Tinzaparin During Slow Low Efficient Daily Dialysis in Intensive Care Patients</brief_title>
  <acronym>Tinza-SLEDD</acronym>
  <official_title>Efficacy, Safety and Pharmacokinetics of Tinzaparin During Slow Low Efficient Daily Dialysis in Intensive Care Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the pharmacokinetics of tinzaparin during renal replacement therapy
      (RRT).

      60 patients with clinical indication for pharmacological thromboprophylaxis and slow low
      efficient daily dialysis (SLEDD) will be studied in Tampere University Hospital. All subjects
      will receive a 4500 IU bolus of tinzaparin. The subjects in study group (n=30) will also
      receive a 4500 IU continuous infusion of tinzaparin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After written informed consent, 60 subjects with clinical indication for pharmacological
      thromboprophylaxis and SLEDD will be studied in the Tampere University Hospital intensive
      care unit. After inclusion the subjects will be randomly assigned into study group (30
      patients) and control (30 patients).

      All subjects receive a bolus of tinzaparin 4500 IU into the inlet line of dialyzer at 5
      minutes after the start of blood pump. Afterwards the subjects in the study group will
      continue to receive continuous tinzaparin infusion (concentration 100 IU/ml) 500 IU/h over
      seven hours. No other heparin product (including arteria flush lines) nor dilution fluids at
      the dialyzer are allowed during the study period of 24 hours. Each SLEDD treatment will be
      performed with Cordiax 5008S (Fresenius) for 8 hours. After the study period of 24 hours
      thromboprophylaxis will be prescribed according to the normal practice in the ICU.

      The primary outcome measure is plasma anti-FXa concentration at 4 hours from the onset of
      SLEDD. Plasma Anti-FXa will be drawn at timepoints 0 hours, 4 hours, 8 hours and 24 hours
      from the onset of the dialysis.

      The clotting formation in RRT system will be evaluated by clotting scoring. In the case of
      serious clotting RRT treatment is stopped and the new RRT is started. The study will end to
      the new RRT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma anti-FXa concentration</measure>
    <time_frame>4 hours from the onset of SLEDD</time_frame>
    <description>Plasma anti-factor Xa blood sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma anti-FXa concentration</measure>
    <time_frame>8 hours from the onset of SLEDD</time_frame>
    <description>Plasma anti-factor Xa blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma anti-FXa concentration</measure>
    <time_frame>24 hours from the onset of SLEDD</time_frame>
    <description>Plasma anti-factor Xa blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clotting Score</measure>
    <time_frame>8 hours from the onset of SLEDD</time_frame>
    <description>Clotting in renal replacement sircuit will be evaluated hourly according to predescribed score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Renal Replacement Therapy</condition>
  <condition>Anticoagulants</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bolus of 4500 IU tinzaparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bolus of 4500 IU tinzaparin and continuous infusion of 4500 IU tinzaparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin continuous infusion</intervention_name>
    <description>4500 IU continuous infusion of Tinzaparin</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin bolus</intervention_name>
    <description>4500 IU bolus of Tinzaparin</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Critically ill patients requiring intensive care

          -  Indication for pharmacological thromboprophylaxis

          -  Written informed consent obtained from the patient or his/her legal representative

          -  Indication for SLEDD, any of following:

          -  serum creatinine concentration of more than 354 micromol/l or greater than 3 times the
             baseline creatinine level OR

          -  anuria (urine output of 100 ml/day) for more than 12 hours OR

          -  oliguria: below 0.3 ml/kg/h for more than 24 hours OR 500 ml/day

          -  the presence of clinically significant organ edema (e.g., pulmonary edema, elevated
             intra-abdominal pressure, significant peripheral swelling) together with oliguria or
             anuria

          -  Dialysis dependence after continuous renal replacement treatment

        Exclusion Criteria:

          -  Other indications for anticoagulant therapy than thromboprophylaxis (including sodium
             citrate for CRRT)

          -  Any long-term anticoagulant or antithrombotic medication, except for low-dose aspirin
             (&lt;150 mg daily)

          -  Treatment with tinzaparin or any other LMWH or heparin within 24 hours of study
             inclusion

          -  Known heparin induced thrombocytopenia (HIT), or hypersensitivity to tinzaparin or any
             other heparin

          -  Known pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Kuitunen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Kuitunen, MD, PhD</last_name>
    <phone>+358331165544</phone>
    <email>anne.kuitunen@pshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simo Varila</last_name>
    <phone>+358505128189</phone>
    <email>simo.varila@pshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Kuitunen, PhD</last_name>
      <phone>+358 3 311 65544</phone>
      <email>anne.kuitunen@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Annukka Vahtera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ville Jalkanen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

